An expert discusses how rilzabrutinib’s oral administration and broad tolerability make it a practical treatment option while ...

A panelist discusses how immune thrombocytopenia (ITP) is characterized by isolated low platelet counts due to autoimmune destruction, with classification based on duration (acute, extended, or ...

Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and ...

The addition of ianalumab to eltrombopag significantly prolonged the duration of safe platelet levels. Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in ...

Neutropenia involves a low neutrophil count, and thrombocytopenia involves a low platelet count. Certain conditions, infections, or medications may cause reduced levels of both. Neutropenia and ...

Novartis AG (NYSE:NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously ...

Noncancerous blood disorders are conditions that affect blood cells, such as red blood cells, white blood cells, and platelets. Blood disorders may cause symptoms and complications, but most are ...

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

LOUISVILLE, Ky., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Onco360 ®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Sanofi for Wayrilz (rilzabrutinib), which ...

Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA ...